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Abstract
Institutional Review Boards (IRBs) are an important checkpoint for all types of research in medicine. Although these
bodies originated primarily in the developed world, they have special contemporary consideration in the context
of developing countries due to the large number of clinical trials being conducted in these regions with the
financial support of large pharmaceutical companies. IRBs are vital to ensure that all scientific investigation is
conducted in a manner that is transparent, scientifically feasible and ethically sound. However, they have also been
variably criticized for introducing unnecessary and often protracted bureaucracy and red tape into the system.
There is a need to reorganize and better delineate the exact functions of the IRBs in view of the dynamic changes
in the realm of research so that they can function in a more efficient, judicious and effective fashion.
Background
Institutional Review Boards (IRBs) are “the officially
empowered guardians of the rights and welfare of
human research subjects” [1]. These bodies have gradu-
ally evolved to become essential check points for all
types of research in medicine. They function as the
“final arbiter of scientific inquiry” [2] and play a central
role in the approval, evaluation, review and monitoring
of research [3].
Historical perspective
The conception of IRBs can be attributed to the process
of peer-review in scientific literature [1] and primarily
originated in the developed world. The two events that
most significantly underlined the need for having agen-
cies such as the IRB to oversee research activities invol-
ving human participants are the Nuremberg Doctor’s
Trial and Tuskegee Syphilis Study. The former occurred
in the aftermath of World War II whereby Nazi scien-
tists were tried for war crimes involving human experi-
mentation. Consequently, the Nuremberg Code was
formulated in 1947 by the Nuremberg Military Tribunal
as a 10-point statement. The most salient feature of this
code was that ‘all participation in research must be
voluntary’ [4]. In the Tuskegee Syphilis Study, about 400
African American patients diagnosed with syphilis were
included. The aim of this study was to observe the nat-
ural course of the disease. However, these patients were
not given effective treatment for syphilis, even though
effective therapies for syphilis had been discovered by
that time.
These events led to the formulation of multiple docu-
ments that have championed the cause of research sub-
jects and research ethics. These include the Declaration of
Helsinki in 1966, Dr. Beecher’s essay ‘Ethics and Clinical
Research’ in 1966, the National Research Act in 1974, the
Vancouver Group’s recommendations, the landmark Bel-
mont Report in 1979, the Common Rule in 1981, the
Food and Drug Administration (FDA) regulations in 1980
and 1981 in the United States (U.S.), the Council for Inter-
national Organizations of Medical Sciences’ (CIOMS)
manual ‘International Ethical Guidelines for Biomedical
Research involving Human Subjects’ in 1982, the Guide-
line for Good Clinical Practice (GCP) in 1996 and the
National Bioethics Advisory Commission’s (NBAC) report
in 1998 [4,5]. A detailed analysis of these documents
reveals that although there is a general consensus over the
rudimentary principles of ethical research, there are many
areas where such concurrence is lacking [4].
Merits of IRBs
There is an ever increasing scope of research in the con-
temporary era. Myriad innovations in medicine need to
be investigated in a systematic fashion before their main-
stream implementation [1]. Authors are required by jour-
nals to comply with the guidelines of their respective
IRBs and to obtain IRB approval before embarking on
any scientific venture. These guidelines are usually based
on institutional and national recommendations as well as * Correspondence: taimur@gmail.com
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ment of Ethical Principles for Medical Research [3].
Several instances in recent years have strengthened the
case and need for approval of research studies by regula-
tory research bodies such as IRBs. In 2007, the Nigerian
government and local government of Kano filed two
separate lawsuits against a large pharmaceutical com-
pany for $7 billion and $2 billion respectively. The com-
pany was sued on multiple accounts including failure to
obtain parental consent and federal approval before giv-
ing the experimental antibiotic trovafloxacin to 100 chil-
dren with meningococcal meningitis in Kano; additional
allegations were leveled against the company for use of
an antibiotic that caused deafness, paralysis, brain
damage, blindness, and death in children [6]. Interest-
ingly, the FDA had not approved the drug in question
for use in children. In adults, the drug was approved for
use in 1997, but withdrawn in 1999 and currently is
restricted for use only in life-threatening infections [6].
The importance of IRBs has also been highlighted by
the misconduct of some researchers. There are reports
that have implicated investigators at highly reputed aca-
demic centers in the U.S. for conducting experimental
research in other regions of the world such as India and
China without the knowledge or consent of their univer-
sity or government or without a proper ethics review of
their research protocol [6].
IRBs are thus vital to ensure that all scientific investi-
gation is conducted in a manner that is transparent,
scientifically feasible and ethically sound. Subjecting
study protocols to stringent rules and regulations also
provides a potential shield against litigation for the insti-
tution where the research is being conducted [2].
Another merit of IRBs is that the subjects are also
potentially protected from interference by funding
bodies and sponsoring agencies [1]. Sponsorships from
industrial giants indeed make it possible to conduct
large scale, multicenter trials. However, such sponsor-
ships can potentially give these agencies leverage to
manipulate how a trial is conducted with a possibility of
comprise in scientific integrity. This can include irregu-
larities in randomization of subjects, testing of unsafe
therapies, “tweaked” or inaccurately performed statistical
analysis, delayed, modified or no reporting of adverse
events and overall outcomes. The presence of IRBs
ensures that scientific integrity is upheld throughout the
process so that the sponsors do not wield undue influ-
ence over the trial. In addition, the privacy and confi-
dentiality of the subjects is protected.
Pitfalls of IRBs
However, despite being championed as the “moral
police” of the district of scientific research, IRBs have
also been criticized for a number of reasons. Quite
simply, IRBs are thought to introduce redundant friction
in the system as they often “go over-board” with the
execution of tasks entrusted to them [2]. They represent
an intrusion of bureaucracy and excessive red tape into
medicine to the extent of being “frustrating”, “conster-
nating” and “paternalistic” for the researchers [2,7].
Most of the procedures and processes of the IRB are
perceived as being extraneous or “extra-regulatory” and
the body itself is often overloaded and understaffed to
handle the ever burgeoning volume of research pre-
sented to it [1].
The decisions made by IRBs are often absolute and
there is little opportunity for investigators to appeal
against their decisions [2]. These decisions maybe per-
ceived by investigators as not based on logic, “bizarre”
[2] or stemming from a clash of egos. Further deter-
rence against IRB scrutiny may stem from fears of losing
important research funding due to the protracted trajec-
tory involved [6]. The stringent requirements of IRB
approval by an increasing number of medical journals
also presents an impediment for independent practi-
tioners and private or nonacademic health centers [3,7].
It should be acknowledged that “guidelines merely
guide...they do not bind” [6]. IRBs are potentially open
to interpret and modify consensus guidelines for con-
ducting research according to loco-regional subtexts;
this introduces an element of variability into the whole
equation [8]. Alternatively, this very facet can be consid-
ered a strength of the IRB system as it leaves a margin
of allowance for the choice of the means used to achieve
a common set of goals [1,5]; an appraisal of the axiom
that ‘no two fingerprints are alike’. Interpretations may
diverge because of differently nuanced personalities,
national trends and even elected personnel in govern-
ment [1]. Subtle conflicts may also exist between the
IRBs if the study is a multi-center one, as is often the
case with large randomized controlled trials. Although
necessary, gaining approval separately from the IRBs at
each of the participating institutions can considerably
tax the financial resources in addition to prolonging the
whole process by several months. Also, researchers
wishing to introduce any change, however small, in the
research protocol have to apply for a re-approval of the
protocol with the new changes from their respective
IRBs [2]. On-going research must also be continually
reviewed by the IRB to detect any safety issues or ethical
breaches etc.
IRBs generally would not have the discretion to with-
hold approval of a safe study even if it is not lucrative
to the university. However, in view of the great financial
recession in the current decade, there could be a conflict
of interest leading to the possibility that IRBs may be
inclined to approve the most feasible, lucrative and per-
haps potentially unsafe studies from investigators who
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This “capitalistic” mindset can undermine the founda-
tion and vision of scientific inquiry in a highly erosive
manner.
IRBs also utilize considerable human work force and
financial resources at academic institutions. In a survey
of 488 IRBs, the average IRB committee was found to
consist of 14 members [9]. In multiple surveys [10,11], it
has been reported that the medial cost incurred by IRBs
ranges between $76,000 to $770,000 per annum (range
$76,000 - $1.15 million). This roughly translates into
$300 to $800 per action. Some detractors of IRBs do
not believe that these bodies, as they are in ineffective
existence today, merit such a high level of spending.
One point that was subsequently raised was that these
studies only focused on academic medical centers,
whereas clinical trials are also conducted by contract
r e s e a r c ho r g a n i z a t i o n sw h i c hm a yb em o r ee f f i c i e n ta s
far as the utilization of resources and human capital is
concerned [12].
At academic medical centers, faculty members either
volunteer or are assigned to contribute their time and
expertise to IRBs [12]. In addition to the significant time
commitment the review of research protocols entails,
this represents an added responsibility beyond what
these faculty members are usually remunerated for. This
may cause a decreased level of motivation among the
members of the IRB and ultimately translate into a sub-
optimal quality of the review process.
Issues in developing countries
A special mention needs to be made of the complexities
arising due to research being conducted in developing
countries. These societies are entrenched in a complex
labyrinth of socio-economic and cultural intricacies,
including a phenomenal veneration for physicians,
which needs to be navigated by the researchers. Interna-
tional research is extremely important in balancing out
inequities in research between the developed and devel-
oping world [13] as less than 10% of global resources
are being spent on 90% of the world’s health issues [14].
However, much hue and cry has also been raised in
recent years over the growing number of international
drug companies who are funding major clinical trials in
the developing world. This change in paradigm is due to
a number of possible reasons including lesser costs, less
red tape, illiterate populace and deficient or malleable
ethical frameworks and monitoring systems in the devel-
oping world; these elements provide a highly fertile
ground for companies to “outsource” trials to the devel-
oping countries [15].
In addition to approval from ethical review commit-
tees in developing countries, ethical approval for such
p r o j e c t si sa l s or e q u i r e df r o mI R B si nt h ed e v e l o p e d
countries where these pharmaceutical giants are usually
based. However, there is no guarantee that both the par-
ticipants and the researchers in the developing world are
fully cognizant of the implications such approval entails.
Much of the paperwork involved, including lengthy con-
sent forms, may be formulated in jargon that is too
complex or altogether unfamiliar for or inapplicable to
the populace in developing countries [16].
In international research done at sites in developing
countries, new therapies are tested against existing
therapies, placebos or “normal standards of care”.H o w -
ever, there is growing debate over the definition of “nor-
mal, fair and reasonable standard of care” in the
developing world. In particular, placebo controlled trials
involving HIV patients came under heavy fire for being
unethical as they did not allegedly compare newer ther-
apy against the current best standard of care [17]. Sup-
porters of such trials have, however, adopted a different
stance on the subject. They argue that in developing
countries, a placebo can be considered as a “prevailing
standard of care” because in the poverty-stricken third
world, the standard of care is often no treatment at all
[18]. At the other extreme, the assumption that the
standards of care in the developed world are the “uni-
versal standards of care” is also flawed [17]. While these
may be the most advanced treatments available, impul-
sively labeling them as the best treatments for the devel-
oping world is not correct, particularly if the argument
is not rationalized in a context-specific manner. Serious
consideration needs to be given to the severe resource
constraints in developing countries where advanced and
often expensive treatment can only be afforded by a
handful of people belonging to the elite strata of society.
The debate on placebo controlled trials is ultimately a
complex one. It should be noted that for some diseases,
the FDA may consider placebo as an acceptable control
in a trial [19]. Therefore, the standard of care in the
developing countries in most instances, if not all, should
not be placebo or ‘no treatment at all’; it should be
‘treatment for all’ - a treatment modality that is accessi-
ble, affordable and morally and medically justifiable.
Also, future debate on “standards of care” needs to con-
sider additional aspects such as structure and efficiency
of the national health system [20]. The structure influ-
ences provision of different levels of care to patients at
different locations while system efficiency influences the
quality of care available in a particular location. Conse-
quently, a “national standard of care” is not synonymous
with a “local standard of care” [20].
At the end of the day, the fundamental question
remains. Are IRBs in the developing world more or less
effective as compared to their counterparts in the devel-
oped world? The answer probably lies in a gray zone
rather than being written in explicitly black and white
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require IRBs to be their ‘guardian angels’ by virtue of
their unique circumstances and socio-demographics.
However, IRBs in the developing world are plagued by
problems such as inconsistency, scarcity, inexperience
and lack of funds [6]. The latter may place research sub-
jects in developing world in a vulnerable position. Anec-
dotal evidence exists that local ethics review committees
do not possess sufficient influence to modify protocols
given by sponsors from the developed world [21].
Solutions
We may consider monetary reimbursement for faculty
members serving on the IRBs to add incentive to this
part of their jobs. More recently, there is a shift towards
reimbursing the members of the IRB for their effort and
time [22]. However, whether this approach will work or
not is debatable as often the primary goal and motiva-
tion behind working in academia is to garner academic
merit and credit [23] rather than pursuit of monetary
benefits.
In the current situation, most of the energy and time
of IRBs is expended in “beating about the bush” -i n
activities that are low-yield, protracted, non-standardized
and seemingly impractical [11,23] that may have led
IRBs to sink into “mission creep” [24]. Excessive focus
on procedures, documentations and definitions only
serves to fulfill perfunctory aspects of research [24]. In a
study assessing IRB processes across 68 U.S. hospitals
for a single multicenter study, it was seen that about
one-third of the IRBs required the principal investigator
to be from the same institution and about 27% required
evidence of human subjects research training [11]. Many
IRBs require multiple copies of the application from the
investigators; still many may not accept an electronic
version of the application. Upto eight copies of the IRB
application were requested at some centers in one study
while less than half of the IRBs had forms available on
their website [11]. Investigators should be allowed to
submit IRB application and all associated materials
o n l i n et os a v et i m ea n dr e s o u r c e s .A l s o ,r e d u n d a n c yi n
the application materials should be avoided as they con-
stitute low-yield procedures that only increase the
review time and the researcher’s frustration without
practically improving subject safety [11]. They also often
distract the IRBs from performing more important func-
tions. In a survey of 488 IRBs, only 58% had a written
policy regarding research integrity - a core dimension of
IRB functioning [9]. Lackey very aptly commented in
one of his papers that, “in moral matters, as in practical
life, it is more important to worry about avoiding disas-
ters than achieving perfection” [18].
One solution to the IRB problem is to make multiple
IRBs at the same institution to deal with research of
different types in order to distribute the workload, better
utilize expertise and expedite review timelines [12].
However, this needs to be reconciled with the fact that
increased functional costs will be incurred from such
administrative “splitting” and “IRB specialization”.
Alternatively, the solution could lie in unifying IRBs at
different academic centers into a “single, cooperative
academic IRB”. The benefits derived from this unifica-
tion would include decreased overall functioning costs,
increased efficiency, and removal of redundancy or
duplication of review necessitated by having IRBs at
every academic center especially for multicenter trials,
ultimately making the whole process more streamlined
[12]. A third solution could be outsourcing the reviews
to “independent” or “commercial” IRBs [16]. In the lat-
ter two scenarios, it would be important to negotiate
the balance of power, authority and control between the
local institution and non-institutional IRB [22].
Perhaps and more importantly, it may be worthwhile
in the long-term to invest in “where the rubber meets
the road” - training of the investigators both in sound
scientific methodology and ethics of research [22]. The
powers that be can churn out one guideline after the
other but they are all fruitless if the morality and ethical
code of researchers with regards to their research sub-
jects is flawed to begin with [15].
For research done in developing countries, it is impor-
tant for IRBs in the developed world to safeguard the
rights of the research subjects in the developing coun-
tries while respecting the wisdom, experience and advice
from IRBs in the developing countries. The drug compa-
nies funding the clinical trials must not be allowed to
exploit the weaker ethical systems in the developing
countries [15]. Profitability must not blind-sight the
regard for the safety of participants. Shortcuts for fulfill-
ing ethical imperatives in developing world should be
avoided [21]. IRBs in the developing world need to be
fully cognizant of the emerging challenges of interna-
tional research in developing countries. Being important
stakeholders in the process, they must participate in the
formulation of principles governing the ethics of inter-
national research. Local empowerment and engendering
sustainable capacity in bioethical study and expertise is
also a very important step in that direction [13]. We
quote the words of Abdallah Daar here, “So long as all
the ethicists are in the North, and the South is just the
recipient of ethical principles, nothing will change!’’
[13,25].
T h ec o m p l e t eu m b r e l l ao fI R Bf u n c t i o n i n ga l s on e e d s
to be evaluated and defined. IRB functions have gradu-
ally expanded to include verification of conflicts of inter-
est, health record confidentiality and waiver of
regulations etc. However, IRBs were not originally
designed, intended or funded to support these additional
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overloaded and understaffed because their functions
have mushroomed without a parallel modification in
structure to buttress these added responsibilities.
Conclusions
IRBs exert considerable influence over the morale of
researchers and the research milieu of an institution
[26]. Discourse continues on whether the modern IRB is
part of the problem or the solution. Are these IRBs the
counterproductive white elephants of science or the
indispensible white knights for legal and ethical impera-
tives in research? Are IRBs the malevolent adversaries
or the honest well-wishers of researchers? [27]
Two interesting paradoxes exist here: first, IRBs police
researchers about the application of evidence-based
methods to conduct research whereas their own proce-
dures have considerable variability due to lack of such
relevant data for their own practices and considerations
[28] and secondly, “a committee is only as ethical as the
members who constitute its body” [15]. IRBs are often
constituted by the colleagues of the investigators who
themselves have conducted research at some point as
well. Ultimately, it is perhaps most appropriate to
describe IRBs as a mixed blessing! Research, especially
involving human subjects, is subject to rigorous regula-
tions in the current medical landscape with good reason.
However, there is a need to take account of the special
administrative and logistic challenges faced by investiga-
tors due to strict red tape from IRBs.
A tt h ee n do ft h ed a y ,w ea c k n o w l e d g et h a ts c i e n t i f i c
inquiry needs to entail appropriate safeguards to the
research subjects. Some researchers, but not all, will
have common scientific sense with an intact moral com-
pass. But all doors don’th a v et h es a m ek e yj u s ta so n e
glove doesn’t fit all; the profile of the genuinely well-
intentioned researcher, therefore, can’t be generalized in
an indiscriminate manner. Martinson et al showed in
2005 that one-third of all scientists in the U.S. had been
involved in research misconduct at some point in the
past 3 years [29]. IRBs exist to provide a much needed
check and balance in the system. However, at the same
time, all research needs to be effectively executed and
efficiently planned to economize resources [30] and
IRBs need to be restructured to better achieve this aim
in the most judicious manner possible [2]. It may better
suit the IRB to be responsive, not reactive, to the
changes in today’s research culture [1].
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